Verbatim response from ChatGPT
Short answer
- On average, Zepbound (tirzepatide) produces larger weight loss in clinical trials than Wegovy (semaglutide).
- Wegovy (and semaglutide products generally) have been easier to find through mainstream telehealth/weight‑loss programs, though availability and cost can vary for both.
Why Zepbound tends to work better
- Zepbound (tirzepatide, an incretin that activates both GIP and GLP‑1 receptors) showed larger mean percent weight loss in the SURMOUNT trials (many patients lost ~15–21% of body weight depending on dose and trial length).
- Wegovy (semaglutide, a GLP‑1 agonist) in STEP trials produced large losses too (around ~15% on average), but in head‑to‑head or indirect comparisons tirzepatide has generally achieved greater mean weight loss.
Safety and side effects
- Both are weekly injectable medications and cause similar GI side effects (nausea, vomiting, diarrhea, constipation) and can require dose titration.
- Both carry warnings about possible thyroid C‑cell tumors in rodents and are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2; neither is appropriate for everyone. Work with a clinician to review medical history and meds.
Which is easier to get online
- Wegovy/semaglutide has been more widely integrated into telehealth weight‑loss services and clinics (many services switched earlier to semaglutide), so it tends to be somewhat easier to access online.
- Tirzepatide (sold as Mounjaro for diabetes and Zepbound for weight management) is increasingly offered but availability has been more variable; some online clinics are cautious because of supply and regulatory scrutiny, and many providers historically prescribed Mounjaro off‑label for weight loss rather than the new branded Zepbound indication.
- Cost and insurance coverage are important barriers for both—list prices are high and coverage varies by insurer and indication.
Where to look online (reputable options)
- Telehealth/weight‑loss services that commonly evaluate and prescribe GLP‑1 or GIP/GLP‑1 therapies: Hims & Hers, Ro (Roman), PlushCare, One Medical, and specialty digital programs like Calibrate. These providers will do a telemedicine visit, review history, order labs if needed, and prescribe if appropriate.
- Pharmacy/coupon help: GoodRx and SingleCare can help compare prices; both Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) run patient-assistance or savings programs—check manufacturer sites for eligibility.
Practical recommendation
- If maximum efficacy is your primary goal and you have no contraindications, tirzepatide (Zepbound) typically shows greater weight loss in trials.
- If you want the option that’s more commonly available right now through online weight‑loss programs, semaglutide (Wegovy or semaglutide products) is often easier to access.
- Next step: discuss with your primary care doctor or an obesity medicine specialist (or use a reputable telehealth service named above). They’ll review safety, insurance, and whether a trial of one of these medications is appropriate for you.
If you want, tell me whether you already have a primary care provider or want a telehealth option and I can suggest one or help draft questions to ask a prescriber.